跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CF3CN
首页
药物
CF3CN
CF3CN
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
DRUG FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE
申请人: SHENZHEN UNIV OF ADVANCED TECHNOLOGY
优先权: 2023
EP
US
WO
3 件公开
Drug for preventing and/or treating alzheimer's disease
申请人: SHENZHEN UNIV OF TECHNOLOGY
优先权: 2023
CN
USE OF INHIBITOR OF TRANSCRIPTION FACTOR C/EBPβ IN PREPARING MEDICAMENT FOR TREATING POSTMENOPAUSAL OSTEOPOROSIS
申请人: SHENZHEN UNIV OF ADVANCED TECHNOLOGY
优先权: 2024
WO
4-(6-OXO-2-(TRIFLUOROMETHYL)-3,6-DIHYDROCHROMENO[7,8-D]IMIDAZOL-8-YL)BENZONITRILE FOR USE IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH MOVEMENT DISORDERS
申请人: ONTRACK THERAPEUTICS LTD
优先权: 2022
US
4-(6-OXO-2-(TRIFLUOROMETHYL)-3,6-DIHYDROCHROMENO[7,8-D]IMIDAZOL-8-YL)BENZONITRILE FOR USE IN THE TREATMENT OF POSITIVE SYMPTOMS IN SCHIZOPHRENIA
申请人: ONTRACK THERAPEUTICS LTD
优先权: 2023
CN
WO
2 件公开
Application of transcription factor C/EBP beta inhibitor in preparation of medicine for treating postmenopausal osteoporosis
申请人: SHENZHEN UNIV OF TECHNOLOGY
优先权: 2024
CN
COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA
申请人: ONTRACK THERAPEUTICS LTD
优先权: 2023
CN
EP
US
WO
4 件公开
SALT FORMS OF A CHROMENE COMPOUND
申请人: ONTRACK THERAPEUTICS LTD
优先权: 2023
WO
药物
反馈